ZURICH, April 22 (Reuters) - Swiss drugmaker Roche (ROPC.S), opens new tab on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting ...

Multiple sclerosis (MS) is most prevalent in Northern Europe and Canada, and more common in the northernmost latitudes. In ...

Roche (RHHBF) (RHHBY) has announced plans to seek regulatory review for an experimental therapy for multiple sclerosis, an autoimmune condition affecting the central nervous system, even as its ...

Roche Holding AG’s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage studies, but more patients died while on the medicine, perpetuating safety ...

Cannabis has been legalised for medial use since 2018 ...

Application Filed to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis ...

Alembic Pharmaceuticals Limited ( (IN:APLLTD)) has issued an update. Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug ...

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...

Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. The Swiss drugmaker Roche on Tuesday presented the latest data for its ...

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its ...

Eric Powers was left with complex neurological problems ...